Abstract |
Objective: To discover the function of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in ASXL1-mutated acute myeloid leukemia (AML) patients.Methods: We analyzed the prognostic value of ASXL1 mutations and explored the role of allo-HSCT in 581 AML patients.Results: According to the definition of intermediate- and adverse-risk AML groups in the European Leukemia Net (ELN), ASXL1-mutated patients had shorter OS and DFS than ASXL1-wild-type patients in the intermediate- and adverse-risk AML groups (3-year OS: 47.5% vs. 60.8%, P<0.001; 3-year DFS: 28.5% vs. 48.9%, P<0.001). Among the cytogenetically normal acute myeloid leukemia (CN-AML), differences were found in both OS (47.4% vs.65.2%, P<0.001) and DFS (21.0% vs. 52.1%, P<0.001) between ASXL1-mutated patients and ASXL1 wild-type patients.In the ASXL1-mutated AML cohort, the patients received allo-HSCT had longer 3-year OS (P=0.0005) and 3-year DFS (P<0.0001) than those who did not receive allo-HSCT. Multivariate analysis revealed that ASXL1 mutation was an independent prognostic factor for OS (HR 2.248, 95% CI 1.155-4.375, P=0.017), and allo-HSCT had a positive impact on OS (HR 7.568, 95% CI 3.597-15.92, P<0.001) and DFS (HR 2.611, 95% CI 1.688-4.039, P<0.001) in ASXL1-mutated patients.Conclusion: The results indicate that the presence of ASXL1 mutations is a factor predictive of poor prognosis in AML patients and allo-HSCT could improve the survival of AML patients with ASXL1 mutations.
|
Authors | Lili Zhou, Jingnan An, Chang Hou, Zixuan Ding, Huiying Qiu, Xiaowen Tang, Aining Sun, Suning Chen, Yang Xu, Tianhui Liu, Depei Wu |
Journal | Hematology (Amsterdam, Netherlands)
(Hematology)
Vol. 26
Issue 1
Pg. 340-347
(Dec 2021)
ISSN: 1607-8454 [Electronic] England |
PMID | 33840380
(Publication Type: Journal Article)
|
Chemical References |
- ASXL1 protein, human
- Repressor Proteins
|
Topics |
- Adolescent
- Adult
- Aged
- Child
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Leukemia, Myeloid, Acute
(epidemiology, genetics, therapy)
- Male
- Middle Aged
- Mutation
- Repressor Proteins
(genetics)
- Survival Analysis
- Transplantation, Homologous
- Treatment Outcome
- Young Adult
|